![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
||
![]() |
|||||
![]() |
PROFESSOR HIDEKI MOCHIZUKI |
||||
![]() |
![]() |
Osaka University hmochizuki@neurol.med.osaka-u.ac.jp |
|||
![]() |
WEBSITE | ||||
![]() |
|||||
![]() |
|||||
![]() |
|||||
![]() |
|||||
Jump to: | |||||
SEMINAR | BIOGRAPHY | ||||
Monday 16th November | Session Six | ||||
Parkinson’s disease and α-synuclein Abstract |
|||||
Dr. Mochizuki is currently Professor and Chair of the Department of Neurology at Osaka University in Osaka, Japan. Prior to his present position, he served as Professor and Chair of Neurology at Kitasato University in Kanagawa, Japan. He obtained his MD and PhD degrees from Juntendo University in Tokyo, and his neurology residency at Juntendo University (1985-1987) and at Tokyo Metropolitan Neurological Hospital (1987-1989). He then completed a postdoctoral fellowship in the Developmental and Metabolic Neurology Branch of NINDS / NIH in Bethesda, Maryland under the tutelage of Roscoe Brady (1996-1998). He returned to Japan to serve on the faculty of Neurology at Juntendo University for eleven years, rose through the academic ranks until his appointment as Chairman first at Kitasato University (2009-2011) and now at Osaka University (2011-). Honours, Awards and Recognition: Publications: Research interests: Professor Mochizuki’s research interest is Parkinson’s disease with a focus on its pathogenesis using neurochemical, molecular and cell biologic studies as well as novel therapeutic approaches using gene therapy. To date, he has authored 80 original articles and 25 reviews and book chapters. In 2005, he published a paper in the Annals of Neurology describing his innovative discovery of possible neurogenesis in the substantia nigra of Parkinson’s disease affected brains. This provided a rationale for the future development of potential therapeutic strategies aimed at up-regulating neurogenesis in this brain region. Among his other seminal contributions to the literature includes the pioneering discovery of apoptotic changes in Parkinson’s disease brains, a finding subsequently confirmed by several other groups. In a publication in the Proceedings of the National Academy of Sciences, he also demonstrated that the expression of Apaf-1-dominant negative mutant in the substantia nigra inhibits apoptotic cell death in the mouse MPTP model of Parkinson’s disease. His more recent efforts focus on the development of gene therapy for the disease to deliver parkin using AAV vector. He has already demonstrated the feasibility and efficacy of this approach in a chronic MPTP mouse model. Professor Mochizuki’s research has been continuously funded by various Japanese funding agencies including the Ministry of Education, Culture, Sports, Science & Technology, the National Institute of Biomedical Innovation, and the Mitusi Life Social Welfare Foundation. Selected publications: 1. Mochizuki H, Goto K, Mori H, Mizuno Y, Histochemical detection of apoptosis in Parkinson's disease, J Neurol Sci, 137, 120-123, 1996.
|
|||||